v3.26.1
Stockholders' Equity (Tables)
 3 Months Ended
Mar. 31, 2026
Stockholders' Equity Note [Abstract]  
Stock-based Compensation Expense
Stock-based compensation related to our stock-based awards and employee stock purchase plan for the three months ended March 31, 2026 and 2025 is as follows (in thousands):
 Three Months Ended
March 31,
 20262025
Cost of net revenues$1,620 $1,538 
Selling, general and administrative
28,992 30,866 
Research and development10,312 12,593 
Total stock-based compensation$40,924 $44,997 
Summary Of Restricted Stock Units
A summary for the three months ended March 31, 2026 is as follows:
Number of Shares
Underlying RSUs
(in thousands)
Weighted Average Grant Date Fair ValueWeighted Average Remaining
Contractual Term (in years)		Aggregate
Intrinsic Value
(in thousands)
Unvested as of December 31, 2025
1,250 $256.80 
Granted
770 189.99 
Vested and released(430)287.72 
Forfeited(33)235.20 
Unvested as of March 31, 2026
1,557 $215.68 1.98$266,886 
Summary of MSU Performance Activity
The following table summarizes the MSU performance activity for the three months ended March 31, 2026: 
Number of Shares
Underlying MSUs
(in thousands)
Weighted Average Grant Date Fair Value
Weighted Average
Remaining
Contractual Term (in years)
Aggregate
Intrinsic Value
(in thousands)
Unvested as of December 31, 2025
263 $507.88 
Granted149 378.44 
Vested and released1
(59)629.53 
Forfeited(28)559.27 
Unvested as of March 31, 2026
325 $421.83 2.14$55,691 
1 Includes MSUs vested during the period below 100% of the original grant as actual shares released are based on our stock performance relative to a market index over the vesting period.
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions
The fair value of the option component of the 2010 Purchase Plan shares was estimated at the grant date using the Black-Scholes option pricing model with the following weighted average assumptions:
 Three Months Ended
March 31,
 20262025
Expected term (in years)1.01.1
Expected volatility44.3 %40.9 %
Risk-free interest rate3.6 %4.2 %
Expected dividends— — 
Weighted average fair value at grant date$55.37 $70.62